PATH Stock: Buy or Sell? Price Target & Forecast

PATH UiPath Inc As of Sep 10, 2026

$13.57

Growth-stage software with strong margins; valuation stretched vs. growth; insider selling pressure; recent analyst upgrade vs. market skepticism.

Setup: Growth / Recovery Confidence: 62 Horizon: 3-6 months Risk: medium-high Category: Growth Software

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals PATH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Strong gross margins (83%), recent Citi buy initiation with $23 target, 15% YoY revenue growth, enterprise RPA/automation demand durability, healthy balance sheet (current ratio 2.48). AI orchestration narrative emerging as scaling lever.

▼ Bear Case

Forward P/E 25x vs. 15% growth — PEG ~1.7, stretched valuation. Heavy insider selling (116 sells vs. 10 buys over trailing period). Operating margin only 3.5% despite 83% gross margin — execution risk on leverage. Stock down 32% from 52w high; sentiment weak despite analyst upgrade.

Valuation

OVERVALUED on trailing basis; FAIR if growth/margin story holds — score 58/100

P/E 19x trailing vs. 15% YoY growth implies PEG ~1.3, at parity threshold. Forward P/E 25x is stretched unless OpEx deleverages materially. Strong gross margin (83%) is asset; low operating margin (3.5%) is constraint. P/B 3.2x reasonable for software, but elevated vs. market.

Technical Levels

Support · $13.43 (Today's intraday low; 50-day MA est. ~13.5) · $12.50 (Round number / 20-day MA est.) · $11.80 (200-day MA vicinity; major support) · $9.20 (52-week low)

Resistance · $14.31 (Today's intraday high) · $15.00 (Round number / recent breakout attempt) · $16.50 (50-day MA est. / mid-range) · $19.84 (52-week high)

RSI: unavailable

Financial Health

Score 78/100. Strong liquidity (CR 2.48, QR 2.42); no immediate solvency risk. Debt metrics absent from payload. Book value $3.88 vs. price $13.57 implies market values intangibles (brand, IP, recurring ARR) at ~$9.70/share. Typical for SaaS; sustainable if revenue growth + profitability improvements track.

Catalysts

Q2 2027 earnings release (just posted; transcript available)	Already released; watch for guidance revision next call	high
AI orchestration product adoption metrics (customer wins, ARR acceleration)	Next earnings report, likely Q3 2027	high
Operating margin expansion (OpEx deleveraging)	2-4 quarter trajectory	high
Insider lockup expirations or secondary offering	Unknown; monitor SEC filings	medium
Competitive pressure from Copilot / AI agents (Microsoft, OpenAI)	Ongoing; watch for customer anecdotes	medium

Risk Flags

Insider selling ratio >10:1 (116 sells vs. 10 buys); typical of mature lock-up expiry or founder/exec loss of conviction.

Forward P/E 25x vs. 15% YoY growth; implies market pricing significant acceleration or margin expansion — high bar.

EV/EBITDA 111x extremely elevated; suggests near-zero near-term profitability or EBITDA calculation edge case.

Stock down 32% from 52w high ($19.84) despite $23 analyst target; market pricing higher discount to consensus.

Operating margin 3.5% vs. gross margin 83% signals high OpEx (R&D, S&M) leverage not yet realized in EBIT.

RSI and earnings growth metrics unavailable; limited near-term momentum/quality signals from payload.

Recent news mentions 'agentic AI pilot purgatory' — suggests customer adoption of next-gen AI features still early/uncertain.

See PATH's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock PATH free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

PATH FAQ

Is PATH a buy right now?

UiPath Inc's current read is a Growth / Recovery setup with 62 confidence over a 3-6 months horizon. Valuation: OVERVALUED on trailing basis; FAIR if growth/margin story holds. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is PATH overvalued?

OVERVALUED on trailing basis; FAIR if growth/margin story holds (valuation score 58/100). P/E 19x trailing vs. 15% YoY growth implies PEG ~1.3, at parity threshold. Forward P/E 25x is stretched unless OpEx deleverages materially. Strong gross margin (83%) is asset; low operating margin (3.5%) is constraint. P/B 3.2x reasonable for software, but elevated vs. market.

What are the risks of buying PATH?